Drug Information

Drug General Information
Drug ID
D0939G
Drug Name
Quisinostat
Indication Advanced stage follicular lymphoma [ICD9: 202; ICD10:C82] Phase 2 [1725891]
Target and Pathway
Target(s) Histone deacetylase 4 Target Info Inhibitor [1725887]
KEGG Pathway Alcoholism
Epstein-Barr virus infection
Viral carcinogenesis
MicroRNAs in cancer
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Signaling events mediated by HDAC Class II
Signaling events mediated by HDAC Class III
Signaling events mediated by HDAC Class I
Sumoylation by RanBP2 regulates transcriptional repression
Validated nuclear estrogen receptor alpha network
Reactome NOTCH1 Intracellular Domain Regulates Transcription
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
WikiPathways Endochondral Ossification
Cardiac Hypertrophic Response
Neural Crest Differentiation
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
TarBasePathway
Cell Cycle
MicroRNAs in cardiomyocyte hypertrophy
References
Ref 1725891ClinicalTrials.gov (NCT01486277) A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Ref 1725887Wikipedia: Quisinostat

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.